Debt-to-equity in % of Apellis Pharmaceuticals, Inc. from Q3 2018 to Q3 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Apellis Pharmaceuticals, Inc. quarterly Debt-to-equity history and change rate from Q3 2018 to Q3 2025.
Apellis Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 276 %, a 7.8% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Apellis Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	276	+20	+7.8%	30 Sep 2025
Q2 2025	334	+85.4	+34.3%	30 Jun 2025
Q1 2025	291	+68.4	+30.7%	31 Mar 2025
Q4 2024	254	+57.9	+29.6%	31 Dec 2024
Q3 2024	256	+56.5	+28.3%	30 Sep 2024
Q2 2024	249	+63.4	+34.1%	30 Jun 2024
Q1 2024	223	+27.6	+14.1%	31 Mar 2024
Q4 2023	196	-1.19	-0.61%	31 Dec 2023
Q3 2023	199	-0.13	-0.07%	30 Sep 2023
Q2 2023	186	-93.4	-33.5%	30 Jun 2023
Q1 2023	195	-409	-67.7%	31 Mar 2023
Q4 2022	197	-5.37K	-96.5%	31 Dec 2022
Q3 2022	200	-4.92K	-96.1%	30 Sep 2022
Q2 2022	279	-1.09K	-79.6%	30 Jun 2022
Q1 2022	604	+130	+27.5%	31 Mar 2022
Q4 2021	5.56K	+5.25K	+1694%	31 Dec 2021
Q3 2021	5.12K	+4.79K	+1450%	30 Sep 2021
Q2 2021	1.37K	+1.11K	+420%	30 Jun 2021
Q1 2021	474	+259	+121%	31 Mar 2021
Q4 2020	310	+143	+85.4%	31 Dec 2020
Q3 2020	330	+240	+264%	30 Sep 2020
Q2 2020	263	+218	+479%	30 Jun 2020
Q1 2020	214	+188	+703%	31 Mar 2020
Q4 2019	167	+145	+662%	31 Dec 2019
Q3 2019	90.7	+69.7	+332%	30 Sep 2019
Q2 2019	45.5			30 Jun 2019
Q1 2019	26.7			31 Mar 2019
Q4 2018	22			31 Dec 2018
Q3 2018	21			30 Sep 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.